(19)
(11)
EP 4 441 500 A1
(12)
(43)
Date of publication:
09.10.2024
Bulletin 2024/41
(21)
Application number:
22830715.3
(22)
Date of filing:
05.12.2022
(51)
International Patent Classification (IPC):
G01N
33/50
(2006.01)
G01N
33/566
(2006.01)
A61K
39/00
(2006.01)
(52)
Cooperative Patent Classification (CPC):
G01N
33/5023
;
G01N
33/566
(86)
International application number:
PCT/EP2022/084451
(87)
International publication number:
WO 2023/099788
(
08.06.2023
Gazette 2023/23)
(84)
Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN
(30)
Priority:
03.12.2021
EP 21212178
(71)
Applicant:
Neurimmune AG
8952 Schlieren (CH)
(72)
Inventor:
MICHALON, Aubin
5400 Baden (CH)
(74)
Representative:
Witthoff Jaekel Steinecke Patentanwälte PartG mbB
Postfach 1140
52412 Jülich
52412 Jülich (DE)
(54)
NOVEL POTENCY ASSAY FOR ANTIBODY-BASED DRUGS AND USEFUL MEANS THEREFOR